Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease
| dc.contributor.author | Vassou, A. | en |
| dc.contributor.author | Alymara, V. | en |
| dc.contributor.author | Chaidos, A. | en |
| dc.contributor.author | Bourantas, K. L. | en |
| dc.date.accessioned | 2015-11-24T19:33:15Z | |
| dc.date.available | 2015-11-24T19:33:15Z | |
| dc.identifier.issn | 0925-5710 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23516 | |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Aged, 80 and over | en |
| dc.subject | Anemia, Hemolytic, Autoimmune/diagnosis/*drug therapy | en |
| dc.subject | Antibodies, Monoclonal/*administration & dosage | en |
| dc.subject | Antibodies, Monoclonal, Murine-Derived | en |
| dc.subject | Chronic Disease | en |
| dc.subject | Cyclophosphamide/*administration & dosage | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Remission Induction | en |
| dc.subject | Salvage Therapy | en |
| dc.title | Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease | en |
| heal.abstract | Cold agglutinin disease (CAD) is an uncommon autoimmune hemolytic anemia characterized by B-cell proliferation. Conventional therapies for primary CAD such as corticosteroids, oral alkylating agents, splenectomy, interferon alpha, and plasma exchange are often ineffective at controlling the disease. The anti-CD20 monoclonal antibody rituximab (MabThera) depletes B-lymphocytes and thereby interferes with the production of cold agglutinin. We describe an elderly patient with primary (idiopathic) chronic CAD refractory to steroids who was successfully treated with 4 weekly infusions (375 mg/m2) of rituximab and 6 months of oral cyclophosphamide at a dosage of 60 mg/m2 per day. The increase in hemoglobin level and the decline in the plasma cold agglutinin titer were rapid (from the second rituximab infusion). The hematologic remission persisted for at least 8 months after treatment start, with no adverse effects. Rituximab and cyclophosphamide may be supplementary therapeutic modalities whose combination warrants further clinical investigation. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/16158824 | - |
| heal.identifier.secondary | http://www.springerlink.com/content/ml7fjrcrawu8bym8/fulltext.pdf | - |
| heal.journalName | Int J Hematol | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2005 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: